FASgen, Inc., a drug development company, was awarded a new $1.4m SBIR Phase II NIH grant for continued research for obesity.
The Baltimore, Maryland-based company, which was founded in 2000, has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway on the regulation of appetite and weight loss. The research is in part conducted in cooperation with laboratories at Johns Hopkins University under a research agreement between the Company and Johns Hopkins.
Commenting on the funding, Susan Medghalchi, Ph.D., FASgen’s principal investigator, said: “This grant supplements the Company’s extensive product development efforts in the metabolic disease field”.
FinSMEs
30/09/2009